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Aims: To investigate the association between circulating non-transferrin-bound iron [NTBI], and markers of
oxidative stress, endothelial function and inﬂammation in subjectswith type2diabetes andnon-diabetic subjects
with varying degrees of obesity.
Methods: Plasma NTBI was measured by HPLC, together with total iron, iron-binding capacity, transferrin
saturation and soluble transferrin receptor, together with total and reduced ascorbate, malondialdehyde [MDA],
E-selectin and high-sensitivity c-reactive protein [hs-CRP] in groups of 28 subjects with type 2 diabetes, 28 non-obese
controls and 17 obese non-diabetic subjects.
Results: Levels of NTBIwere higher than controls in the diabetes group, but the total serum iron levelswere lower.
MDA levelswere higher than controls in both the diabetes and obese groups, and thiswas associatedwith higher
levels of oxidised ascorbate. hs-CRP levelswere higher in both the diabetes and obese groups, and E-selectinwas
signiﬁcantly higher in thediabetes group. Therewere strongpositive correlationsbetweenHbA1c levels andNTBI
[P b 0.01], HbA1c and E-selectin [P b 0.001] and NTBI and E-selectin [P b 0.02] in the diabetes group.
Conclusion: These results support the hypothesis that iron-mediated oxidative stress may be a mechanism
linking poor glycaemic control with vascular dysfunction in type 2 diabetes.
© 2015 Elsevier Inc. All rights reserved.1. Introduction
Diabetes and obesity are two closely associated conditions both
carrying a risk of cardiovascular disease (Hubert, Feinleib, McNamara, &
Castelli, 1983; Kannel & McGee, 1979). Although many factors
are thought to inﬂuence the predisposition to cardiovascular disease
the underlyingmechanisms remain controversial. There is evidence that
iron dysregulation may play a signiﬁcant role in the vascular complica-
tions of diabetes, and cardiovascular disease in non-diabetic subjects
(Basuli, Stevens, Torti, & Torti, 2014; Vinchi et al., 2014). In general, most
studies have shown evidence of excessive iron stores in subjects with
diabetes, while obese subjects tend to be iron deﬁcient using standard
methods of assessment (Yanoff et al., 2007; Zafon, Lecube, & Sim , 2010).terestwith regard to thiswork.
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al of Diabetes and Its CompliHowever, the most appropriate methods to measure iron status and its
potential impact on CVD risk are currently unclear.
Body iron is known to be present in a number of forms
(Waldvogel-Abramowski et al., 2014), not all of which are available
to contribute to the development of atherosclerosis or endothelial
dysfunction. Within the body iron pool, it is generally considered that
iron which is not sequestered on transferrin or bound to other
iron-binding proteins, referred to as non-transferrin-bound iron
[NTBI] contains a proportion of redox active iron capable of inducing
oxidative damage to cells and tissues (Brissot, Ropert, Le Lan, & Loréal,
2012). This is a relatively small component of total iron stores but is
potentially highly reactive (Brissot et al., 2012). The exact nature of
NTBI remains to be elucidated, although it is considered that iron
complexed with citrate may represent the major form (Brissot et al.,
2012). Under certain conditions iron-citrate complexes are redox
active and may contribute to oxidative damage to tissues (Adam,
Bounds, Kissner, & Koppenol, 2015). Standard biomarkers for iron
status such as ferritin and soluble transferrin receptor concentrations
do not necessarily provide an accurate monitor of NTBI levels. In some
cases changes in NTBI levels do follow changes in the levels of the
standard biomarkers (Goto et al., 2013), but in others this is not so
(Porter et al., 2014). Such ﬁndings have led to the suggestion that NTBI
should be included as a valid independent biomarker of theis associated with biomarkers of oxidative stress, inﬂammation and
cations (2015), http://dx.doi.org/10.1016/j.jdiacomp.2015.05.017
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Taher et al., 2009).
The aim of this study, therefore, was to test the hypothesis that NTBI
is a biomarker associated with indices of oxidative stress, inﬂammation
and vascular dysfunction in individuals with type 2 diabetes and also in
non-diabetic subjects with varying levels of obesity.
2. Materials and methods
2.1. Subjects
The study was approved by the National Health Service research
ethics committee, and participants gave written informed consent.
The study was conducted in accordance with the principles of the
Declaration of Helsinki and Committee on the Harmonisation of
Good Clinical Practice (Dixon, 1999). The study population was
comprised of 73 subjects all aged N40 years: 28 had type 2 diabetes,
recruited from diabetes clinics, 28 were lean healthy control subjects
recruited by advertisement, and 17 were obese non-diabetic
subjects recruited from diabetes clinics; 17 were obese non-diabetic
subjects recruited from the general population andweightmanagement
clinics. Based on conservative assumptions on mean and standard
deviation for NTBI measurements from previously published data (Lee
et al., 2006) we estimated that a sample size of 23 subjects per group
would give at least 90% power to detect a signiﬁcant difference in NTBI
between the diabetic and comparator control groups at the 5%
signiﬁcance level (http://www.stat.ubc.ca/-rollin/stats/ssize/). In sup-
port of this calculation, Leoncini et al. (2008) reported signiﬁcant
differences in NTBI levels between controls and subjects with diabetes
using 24 subjects per group.We therefore set a recruitment target of 30
subjects per group, which would allow for up to 20% drop-outs.
Patients with diabetes had been suffering from the condition for
1–22 years post-diagnosis (mean ± SD: 9.79 ± 5.24 years). Recruit-
ment occurredbetweenNovember 2012 andNovember 2013. All diabetic
subjects were receiving treatment to improve insulin sensitivity. Most
(23) received metformin while others were treated with related drugs
e.g., ploglitazone. Some subjects (12) also received treatment to improve
insulin secretion, while others (7) received insulin or insulin substitute
therapy. Only two of the subjects were treated for other morbidities, one
for heart disease and one for asthma/COPD.
Anthropometric indices were measured which included BMI, body
fat percentage (Tanita TBF-300MA Body Composition analyser, Tanita
UK) and waist-to-hip ratio in a single visit. Each subject supplied
3 × 3 ml blood samples using Vacutainers (Becton Dickinson,
Plymouth, UK), one with lithium heparin as anticoagulant, one with
EDTA as anticoagulant and one plain tube for serum. Blood samples in
EDTA and lithium heparin tubes were centrifuged at 1,000×g for
5 min to provide plasma; the blood in the plain tubes was centrifuged
after 30 min at room temperature, and then plasma and serum were
stored at−80 °C prior to biochemical analysis. From the EDTA plasma
400 μl were removed and added to 400 μl of 10%metaphosphoric acid
(MPA) containing 2 mM EDTA and then centrifuged at 20,000×g at
4 °C for 10 min. The supernatant was removed and stored at−80 °C
prior to the measurement of ascorbate.
2.2. Materials
Light magnesium carbonate, disodium EDTA, metaphosphoric acid,
acetonitrile, ethanol, KCl, KH2PO4, NaCl, Na2HPO4•12H2O, FeCl3•6H2O,
Tris(2-carboxyethyl) phosphinehydrochloride (TCEP), phosphoric acid,
1,2-dimethyl-3-hydroxy-4(1H)-pyridinone (DHP), nitrilotriacetic acid
(NTA), butylated hydroxytoluene, thiobarbituric acid and all other
laboratory reagents were obtained from Sigma-Aldrich (Poole, UK) or
Fisher Scientiﬁc (Loughborough, UK). Amicon Ultra ﬁlter units (0.5 ml,
30 kDa cut off) were purchased formMerck-Millipore (Fisher Scientiﬁc
Loughborough, UK). ELISA kits for the measurement of E-SelectinPlease cite this article as: Aljwaid, H., et al., Non-transferrin-bound iron
endothelial dysfunction in type 2 d..., Journal of Diabetes and Its Compliand hsCRP were obtained from Biorbyt, UK. The ELISA kit for the
measurement of soluble transferrin receptor was obtained from
Biovendor, UK.
2.3. Measurement of total iron and total iron-binding capacity
Total iron and total iron-binding capacity were assessed by a
scaled down version of the methods recommended by the Interna-
tional Committee for Standardisation in Haematology as described
previously (Collard, White, & Copplestone, 2014). 400 μl of extracel-
lular phase, blanks and standards were added to 400 μl of protein
precipitation solution (0.6 M TCA and 0.4 M thioglycolic acid in 1 M
HCl). This was mixed thoroughly for 1 minute and incubated at 56 °C
for 15 minutes in a water bath. The samples were cooled and
centrifuged for 5 minutes at 1,000×g to provide an optically clear
supernatant. 500 μl of this was added to 500 μl of ferene 0.5 mM
{3-(2-pyridyl-5,6-bis-[2-5-furyl sulphonic acid]-1,2,4 triazine} in
1.5 M sodium acetate. This was incubated for 5 minutes before
absorbance was measured at 593 nm in a spectrophotometer. Iron
concentration was computed from the absorbance of standards
included in each batch of samples.
To determine iron-binding capacity, 350 μl of plasmawas added to
350 μl of iron saturating solution (100 μM FeCl in 5 mM HCl). This
was mixed and allowed to stand at room temperature for 5 minutes.
35 mg of lightmagnesium carbonate was then added, and themixture
agitated for 30 minutes. Themagnesium carbonatewas then removed
by two sequential centrifugation steps of 1,000 × g for 5 minutes.
400 μl of the resultant supernatantwas removed for themeasurement
of iron as described above.
2.4. Measurement of non-transferrin-bound iron [NTBI]
NTBI was measured using a slight modiﬁcation of the HPLC method
of Kime, Gibson, Yong, Hider, and Powers (1996). Brieﬂy, 300 μl of
plasmawas incubated with 30 μl of 0.8 M nitrilotriacetic acid [NTA] for
20 minutes at room temperature to chelate loosely bound iron, such as
that chelated with residual citrate or albumin. The samples were then
placed in 30 kDa Amicon Ultra 0.5 mlﬁlters (Millipore) and centrifuged
at 13,000×g at 4 °C for 30 minutes. 250 μl of the ultraﬁltrate were
removed and incubated with 25 μl of 35 mM 3-hydroxy-1-propyl-2-
methyl-pyridon-4-one for 5 minutes before injecting into the HPLC
system (sample loop 20 μl). The mobile phase consisted of 5 mM PIPES
buffer pH7.0 containing 3.5 mM3-hydroxy-1-propyl-2-methyl-pyridon-4-one
and 5% acetonitrile. The columnwas a PEEK lined 100 mm × 5 mmC18
column (Hichrom). All tubingwas PEEK. Themobile phasewas pumped
at a ﬂow rate of 1 ml/minute using a Dionex pump. The absorbance of
the iron-chromophore complexwas determined using a Dionex UV/VIS
detector at a wavelength of 450 nm, and chromatography conducted
using Chromeleon software. The concentration of NTBI was computed
from blanks and standards taken through the whole procedure with
each batch of samples. The coefﬁcient of variation calculated using a
range of NTBI concentrations over a number of days ranged from 3.79%
to 7.50%.
2.5. Measurement of ascorbate
Total and oxidised ascorbateweremeasured by themethod of Sato
et al. (2010). Two aliquots of 90 μl were removed from the initial MPA
extract. To one of these 10 μl of 5% MPA were added. A further 200 μl
of 5% MPA was added, the sample mixed and injected into the HPLC
system (20 μl sample loop). This provided the value for reduced
ascorbate. To the other aliquot, 10 μl of tris (2-carboxyethyl) phosphine
hydrochloride [TCEP] was added, and the mixture incubated at room
temperature for 20 minutes to convert all the oxidised ascorbate to the
reduced form. 200 μl of 5%MPAwas then added, the sample mixed and
injected into the HPLC system. This provided a measure of totalis associated with biomarkers of oxidative stress, inﬂammation and
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the value for reduced ascorbate from that of the total ascorbate.
The HPLC system consisted of a 150 mm × 4.6 mm ACE 5 AQ C18
column (Hichrom, Reading UK), a Milton Roy Constametric pump
(Milton Roy, Sunderland UK) coupled to a BAS LCD40 electrochemical
detector (BASi West Lafayette IN, USA) set at a voltage of +0.6 V.
The mobile phase consisted of 50 mM phosphate buffer containing
0.54 mM EDTA and 2% methanol at a pH of 2.8. This was pumped at
1.0 ml/minute.2.6. Measurement of malondialdehyde [MDA]
This was measured in this study by the method of Agarwal and
Chase (2002) as described previously (Collard et al., 2014). Plasma
(50 μl) or standard (up to 2 μM) or blankwasmixedwith 50 μl of BHT
(0.05% in 95% ethanol), 400 μl of phosphoric acid (0.44 M) and 100 μl
of TBA (42 mM). The tubes were capped and the contents mixed well
on a vortex mixer. All tubes were heated for 1 h at 100 °C in a dry
block, and then were removed and placed on ice to cool. Butan-1-ol
(300 μl) was added and mixed well using the vortex mixer. The
mixture was centrifuged for 5 min at 13,000×g to separate the
aqueous and butanol phases. Two hundred microliters of the butanol
extract were removed carefully and placed in tubes ready for injection
directly into a Dionex Ultimate 3000 HPLC system (Thermo Fisher
Scientiﬁc) comprising an Ultimate 3000 pump and Ultimate 3000
ﬂuorescence detector. Chromatography was conducted using a
100 mm × 4.6 mm Hichrom C18 column, protected by a guard column
of the same resin and a 2 μm inline ﬁlter (Hichrom). Chromatography
wascontrolledusingChromeleon software (version6.8) (ThermoFisher
Scientiﬁc). The mobile phase (50 mM potassium phosphate/methanol
80:20 v/v, pH 6.8) was pumped at a rate of 1.0 ml min−1. MDA was
detected using an excitation wavelength of 515 nm and an emission
wavelength of 553 nm.2.7. Assessment of endothelial function
This was determined by the measurement of circulating E-selectin
(Endothelial Leukocyte Adhesion Molecule-1, ELAM-1). E-selectin
was measured by a commercially available ELISA kit (Biorbyt UK)
according to the manufacturer's instructions. The sensitivity of the
assaywasb10 pg/mlwithadynamic rangeof62.5 pg/ml–4,000 pg/ml. The
assay showed no cross reactivity with any cytokine (manufacturer's data).2.8. Measurement of C-reactive protein
C-reactive protein was measured using a commercially available
ELISA kit (Biorbyt UK) according to the manufacturer's instructions.
The sensitivity of the assay was b 10 pg/ml with a dynamic range
of 156 pg/ml–10,000 pg/ml. The assay was speciﬁc for natural and
recombinant CRP (manufacturer's data).Table 1
Demographic details of subjects.
Lean controls
No of subjects 28
Age [mean ± SD] 51.2 ± 6.6 †
Sex F7, M21
BMI [mean ± SD] 22.88 ± 1.71 †
Waist:Hip ratio [mean ± SD] 0.851 ± 0.079 †
% Body fat [mean ± SD] 20.71 ± 5.10 †
HbA1c concentration
Data were analysed by ANOVA with Bonferroni post-hoc tests. Signiﬁcance was set at P b 0
Signiﬁcant differences between groups are shown as follows:
between controls and subjects with diabetes; † between controls and obese subjects; Δ be
Please cite this article as: Aljwaid, H., et al., Non-transferrin-bound iron
endothelial dysfunction in type 2 d..., Journal of Diabetes and Its Compli2.9. Iron status
Serumsoluble transferrin receptor [sTfR] concentration, ameasure of iron
statuswas assessed using a commercially available ELISA kit (BioVendor UK)
according to themanufacturers' instructions. The sensitivity of the assay was
5 ng/ml with a dynamic range of 5 ng/ml–10 μg/ml. The assay was speciﬁc
for human sTfR with no cross reaction with sTfR from other species.
The intra-assay CV was 6.0–7.5%. The inter assay CV was 5.5–7.0%
(manufacturer's data).2.10. Measurement of HbA1c
Glycated haemoglobin (HbA1c) was measured by cation exchange
high-pressure liquid chromatography on a Menarini Biomen HA-8160
analyser. CVs were 1.2% for HbA1c 6% (42 mmol/mol) and 1.1% for
HbA1c 11% (97 mmol/mol).2.11. Data analysis and statistics
Statistical testing was carried out using IBM SPSS 21. Data were
tested for normality using Shapiro–Wilk. Normally distributed data
were tested for differences between groups using ANOVA, with
Bonferroni post-hoc tests. Non-parametric data were tested using
Mann–Whitney U. All tests were 2-tailed, with p set at ≤0.05.
Correlational data were analysed using the Pearson test. There was a
small but signiﬁcant difference in themean ages of the three groups of
subjects (Table 1). In view of this it was necessary to determine the
inﬂuence of this mismatch on the data. This was done by inserting the
data into a general linear model with subject age as a quantitative
factor and subject group as a qualitative factor. In all cases there was
no signiﬁcant interaction between subject age and subject group.3. Results
3.1. Sample groups
There was no correlation between age and any of the parameters
measured except for total iron-binding capacity which declined with
age (r = 0.344: P b 0.01).3.2. Indices of iron status
The measures of iron status are shown in Fig. 1 (charts a–f).
In the diabetes group compared to the control group NTBI, sTfR, and
transferrin saturation were elevated, while total serum iron and TIBC
were lower. NTBI levels and transferrin saturation were higher in the
diabetes group compared to the obese group. The NTBI levels were not
signiﬁcantly higher in the obese group compared to controls, but sTfR
levels were elevated.Type 2 diabetes Obese controls
28 17
57.8 ± 6.8Δ 49.5 ± 9.0
F10, M18 F9, M8
34.25 ± 8.48Δ 38.17 ± 6.35
1.015 ± 0.274Δ 0.916 ± 0.076
35.79 ± 10.33Δ 41.13 ± 8.73
65.75 ± 19.56 mmol/mol 8.164 ± 1.79%
.05.
tween subjects with diabetes and obese subjects.
is associated with biomarkers of oxidative stress, inﬂammation and
cations (2015), http://dx.doi.org/10.1016/j.jdiacomp.2015.05.017
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Fig. 1. Ironmeasures and biomarkers of inﬂammation and endothelial activation in controls (n = 28), type 2 diabetes (n = 28), and obese individuals (n = 17). Data are expressed
as the mean ± 1 SD for parametric data. Signiﬁcant differences between groups are indicated by ⁎, P ≤ 0.05; ⁎⁎, P ≤ 0.01; ⁎⁎⁎, P ≤ 0.001. Individual charts are as follows: (a) total
serum iron; (b) total iron-binding capacity; (c) non-transferrin-bound iron; (d) % of total serum iron present as non-transferrin-bound iron; (e) transferrin saturation; (f) soluble
transferrin receptor; (g) high-sensitivity C-reactive protein; (h) E-selectin.
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Biomarkers of oxidative stress are presented in Table 2. The levels
of MDA, oxidised ascorbate, hsCRP and E-selectin were higher in thePlease cite this article as: Aljwaid, H., et al., Non-transferrin-bound iron
endothelial dysfunction in type 2 d..., Journal of Diabetes and Its Complidiabetes group than in controls, while the level of reduced ascorbate
was lower. Similarly, the levels of MDA, oxidised ascorbate and hsCRP
were higher in the obese subjects than controls, but E-selectin levels
were similar. MDA and E-selectin levels were higher in the diabetesis associated with biomarkers of oxidative stress, inﬂammation and
cations (2015), http://dx.doi.org/10.1016/j.jdiacomp.2015.05.017
Table 2
Biomarkers of oxidative stress.
Controls Diabetes Obese
MDA [μmol/l] 0.946 ± 0.182 † 1.665 ± 0.454Δ 1.215 ± 0.282
Total ascorbate [μmol/l] 66.971 ± 27.185 47.100 ± 16.923Δ 72.732 ± 26.226
Oxidised ascorbate [μmol/l] 6.507 ± 3.318 † 10.337 ± 7.132Δ 16.139 ± 13.128
% Oxidised ascorbate 11.314 ± 7.037 † 22.765 ± 14.859 20.434 ± 12.556
Ratio of oxidised:
Reduced ascorbate
0.135 ± 0.103 † 0.340 ± 0.300Δ 0.291 ± 0.220
Data are expressed as the mean ± SD of 28 subjects (diabetes and control groups) and
17 (obese subjects).
Signiﬁcant differences between groups are shown as follows:
between controls and subjects with diabetes; † between controls and obese subjects;
Δ between subjects with diabetes and obese subjects.
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ascorbatewas highest in the diabetes group,whichwas signiﬁcantly higher
than that of the obese group. Both obese and diabetes groups had higher
oxidised to reduced ratios than the controls.
3.4. Biomarkers of endothelial function and immune status
Biomarkers of endothelial activation and inﬂammation are shown
in Fig. 1 (charts g and h). E-selectin levels were signiﬁcantly higher in
the diabetes group than the controls and obese subjects which were
not signiﬁcantly different. The level of hs-CRP was signiﬁcantly higher
in the diabetes and obese groups than controls.
3.5. Correlation between iron status and parameters of oxidative status,
immune function and endothelial activity
An important ﬁnding of this study was the strong positive
correlation between HbA1c level and NTBI in the diabetic group
(R = 0.521; P b 0.01). There was also a strong positive correlation
between NTBI and E-selectin in this group (R = 0.850; P b 0.001), but
not in the other groups. HBA1c also correlated with E-selectin in the
diabetic group (R = 0.469; P b 0.02).
4. Discussion
There has been considerable interest in the potential role of iron in
diabetes and its complications (Basuli et al., 2014; White & Collinson,
2013), but the complex interactions between iron, reactive oxygen
species and the development of diabetes and its complications are not
fully understood (Simcox & McClain, 2013). The results of this study
have provided strong evidence of the association of NTBI with the risk
of vascular complications of type 2 diabetes.
With regard to overall iron status, the high level of circulating sTfRs
in the obese group is consistent with previous observations of iron
deﬁciency in obesity (Ausk & Ioannou, 2008; Capeda-Lopez et al., 2011).
The higher sTfR levels seen in the diabetes group would also imply iron
deﬁciency which is contrary to the ﬁndings of many previous studies
(see Simcox&McClain, 2013). Themajorityof circulating sTfRsoriginate
from erythroblasts and reticulocytes (Beguin, 2003). However, other
cells which accumulate iron and also express sTfRs include adipocytes.
Furthermore the expression of sTfRs in adipocytes is enhanced by
insulin treatment (Tanner& Lienhard, 1987). The diabetic subjectswere
insulin resistant, overweight and probably hyperinsulinaemic. Hence it
may be suggested that enhanced iron uptake by adipocytes in these
individuals might contribute to the enhanced circulating sTfRs rather
than evidence of iron deﬁciency.
The high level of NTBI observed in the diabetes group in this study
is in agreement with those of Sulieman et al. (2004), Lee et al. (2006)
and Leoncini et al. (2008), but not Van Campenhaut et al. (2006). Of
themethods used tomeasure NTBI, HPLC has been suggested to be the
‘gold standard’ with regard to sensitivity and speciﬁcity (Sasaki et al.,Please cite this article as: Aljwaid, H., et al., Non-transferrin-bound iron
endothelial dysfunction in type 2 d..., Journal of Diabetes and Its Compli2011). The HPLC method used in this study incorporated a number of
the reﬁnements suggested by Sasaki et al. (2011) to optimise the
methodology, and reported similar limits of sensitivity, and mean
values as seen in our control group. Consequently we are conﬁdent
that the NTBI measurements made in this study are an accurate
measure of the availability of circulating ironwhich is not sequestered
with macromolecules.
Elevated circulating levels of NTBI in the diabetic group could have
arisen as a result of poor binding of iron by iron-binding proteins or as a
result of excessive iron entering the circulation fromother sources. In this
study, the amount of iron bound to transferrin in subjects with diabetes
was greater than that seen in controls or obese subjects, suggesting that
decreased ironchelationby iron-bindingproteinsmaynotbe the causeof
the elevated NTBI. The strong positive correlation between HbA1c and
NTBI levels in the diabetic subjects suggests that NTBI availabilitymay be
related to the degree of protein glycation. Protein glycation may in turn
lead to the formationof reactive oxygen species (Resmi, Akhunlar, Temez
Artmann, & Guner, 2005). A number of glycated proteins have been
identiﬁed within the RBC membrane of diabetic patients (Zhang et al.,
2011). Glycation of cell surface proteins of the RBC membrane modiﬁes
the visco-elastic properties of the RBCs which decreases their deform-
ability (Riquelme, Foresto, D’Arrigo, Valverde, & Rasia, 2005) and ability
to pass through ﬁne vessels (Starodubtseva, Kuznetsova, Yegorenkov, &
Cherenkevich, 2008). These changesmaypredisposepatientswith type2
diabetes to an enhanced tendency towards intravascular haemolysis.
This would permit the efﬂux of glycated/oxidatively modiﬁed intra-
cellular components such as Hb and heme which may release free iron
(Collard & White, 2014; Maitra et al., 2011). The changes in MDA and
ascorbate seen in the diabetes group indicate that there is a high level of
oxidative stress occurring in these subjects. Thus, it is possible to
speculate that the increase in NTBI observed in subjects with diabetes
may have derived not from an inability to sequester free iron but from
the functional consequences of protein glycation and oxidative
modiﬁcation of RBCs.
Changes in RBC deformability in a rat model of diabetes occur
before the development of vascular complications (Diamantopoulos
et al., 2004), indicating that the consequences of RBC membrane
dysfunction, as described above, may trigger the vascular events.
Endothelial dysfunction is considered to be the earliest event in
atherogenesis. The strong positive correlation between NTBI and
E-selectin in the diabetic group suggests that endothelial function
may be inﬂuenced by circulating free iron. This is supported by
previous studies which showed that the administration of iron to
healthy individuals induced endothelial dysfunction which was
associated with increased free radical generation (Rooyakkers et al.,
2002) while chelation of iron with deferroxamine led to decreased
induction of E-selectin and other adhesion molecules in an in vitro
model of endothelial activation (Zhang & Frei, 2003). There was a
positive relationship between these parameters in the obese group,
but it did not reach signiﬁcance. This therefore requires further study
with a larger group of obese subjects.
The high levels of inﬂammation seen in both the obese and diabetic
subjects may also contribute to iron-mediated vascular dysfunction.
Part of the inﬂammatory process includes the enhancement of hepcidin
secretion (Ganz&Nemeth, 2009;Nemethet al., 2003).Hepcidin inhibits
the efﬂux of iron frommacrophages (Knutson, Oukka, Koss, Aydemir, &
Wessling-Resnick, 2005). These iron-rich macrophages can enter the
developing atherosclerotic plaque and contribute to iron-induced
pathology (Vinchi et al., 2014). The failure to observe a signiﬁcantly
increasedNTBI level in obese subjects, and a lack of correlation between
NTBI and E-selectin in this group suggests that circulating NTBImay not
be a major atherogenic factor in obese subjects. On the other hand,
locally released iron from macrophages incorporated into the develop-
ing atherosclerotic plaque might be a more likely source (Basuli et al.,
2014; Vinchi et al., 2014). In contrast, while adipokine-mediated
inﬂammation and endothelial dysfunction would, in all probability,is associated with biomarkers of oxidative stress, inﬂammation and
cations (2015), http://dx.doi.org/10.1016/j.jdiacomp.2015.05.017
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activation, oxidative stress and NTBI suggest that the diabetic group
may have an enhanced tendency to develop atherosclerosis whichmay
be related to iron-mediated phenomena resulting from haemolysis as
outlined above.
In conclusion, the results of this study have extended our knowledge
of the relationship between iron and iron-associated substances and
other factors involved in the vascular complications of diabetes. This has
allowed the development of a hypothetical sequence of events to
account for these interactions andwhichmay be investigated by further
study. The datawould support a scenario inwhich the source of the iron
and iron-containing substances is likely to be theerythrocyte, and itmay
be proposed that this derives from a degree of intravascular haemolysis
resulting from glycation-mediated changes in the elasticity and
deformability of the erythrocyte membrane. The released iron and
iron-containing molecules then contribute to endothelial dysfunction
by promoting oxidative damage and other deleterious processes
involved in atherogenesis (Vinchi & Tolosano, 2013; Vinchi et al.,
2014). In contrast, thepotential involvement of irondysregulation in the
vascular complications of obesity is less evident from our data.
5. Strengths and limitations of the study
The study has a number of strengths and some weaknesses. The
major strength of this study was the measurement of a panel of key
parameters in a single subject. This allowed a more comprehensive
analysis of the relationships between the parameters, and provided
the opportunity to develop a working hypothesis of the possible link
between glucose control, iron and atherogenesis in diabetes. The
weakness of the study was the cross-sectional design and limited
sample size, particularly of the obese group, treatment heterogeneity
and the slight difference in the age of the participants in the groups.
Consequently, the sequence of events proposed remains hypothetical.
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